Oral NRX 194204 in Patients With Refractory Malignancies
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This phase I study will determine the safety profile of NRX 194204 on this schedule; it will
evaluate the pharmacokinetic profile of NRX 194204 in cancer patients; and will investigate
anti-tumor activity as manifested by standard response criteria, or by tumor markers.